Pulmonary alveolar proteinosis: from classification to therapy

Area of Science:

• Pulmonary Medicine
• Rare Diseases
• Genetics

Background:

• Pulmonary alveolar proteinosis (PAP) is a rare respiratory syndrome characterized by surfactant lipoprotein accumulation in alveoli.
• PAP is classified into primary (autoimmune or hereditary), secondary, and congenital forms based on underlying pathogenetic mechanisms.
• Primary PAP involves granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling disruption, with autoimmune cases driven by anti-GM-CSF autoantibodies.

Purpose of the Study:

• To provide updated knowledge on pulmonary alveolar proteinosis (PAP).
• To emphasize early diagnosis and appropriate management strategies for PAP.
• To highlight recent therapeutic options tailored to PAP pathogenesis and disease severity.

Main Methods:

• Review of clinical manifestations, diagnostic workup, and current treatment strategies for PAP.
• Analysis of pathogenetic mechanisms including GM-CSF signaling, genetic mutations, and alveolar macrophage dysfunction.
• Evaluation of diagnostic tools such as imaging, laboratory tests (autoantibodies, GM-CSF levels), and genetic testing.

Main Results:

• PAP presents with diverse clinical symptoms, from insidious onset to acute respiratory failure.
• Diagnosis involves a comprehensive approach including clinical assessment, imaging (HRCT), laboratory tests, and genetic analysis.
• Whole-lung lavage is the gold standard, with GM-CSF augmentation and other novel therapies showing promise for specific PAP forms.

Conclusions:

• Accurate classification of PAP based on etiology is crucial for guiding treatment decisions.
• Early and precise diagnosis through integrated diagnostic approaches improves patient outcomes.
• Emerging therapies targeting specific pathogenic pathways offer new hope for managing this rare respiratory condition.